Literature DB >> 18164041

Amphetamine-induced decreases in dopamine transporter surface expression are protein kinase C-independent.

Ekaterina Boudanova1, Deanna M Navaroli, Haley E Melikian.   

Abstract

Amphetamine (AMPH) is a potent dopamine (DA) transporter (DAT) inhibitor that markedly increases extracellular DA levels. In addition to its actions as a DAT antagonist, acute AMPH exposure induces DAT losses from the plasma membrane, implicating transporter-specific membrane trafficking in amphetamine's actions. Despite reports that AMPH modulates DAT surface expression, the trafficking mechanisms leading to this effect are currently not defined. We recently reported that DAT residues 587-596 play an integral role in constitutive and protein kinase C (PKC)-accelerated DAT internalization. In the current study, we tested whether the structural determinants required for PKC-stimulated DAT internalization are necessary for AMPH-induced DAT sequestration. Acute amphetamine exposure increased DAT endocytic rates, but DAT carboxy terminal residues 587-590, which are required for PKC-stimulated internalization, were not required for AMPH-accelerated DAT endocytosis. AMPH decreased DAT endocytic recycling, but did not modulate transferrin receptor recycling, suggesting that AMPH does not globally diminish endocytic recycling. Finally, treatment with a PKC inhibitor demonstrated that AMPH-induced DAT losses from the plasma membrane were not dependent upon PKC activity. These results suggest that the mechanisms responsible for AMPH-mediated DAT internalization are independent from those governing PKC-sensitive DAT endocytosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18164041      PMCID: PMC2716702          DOI: 10.1016/j.neuropharm.2007.11.007

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  52 in total

Review 1.  Chronic and acute regulation of Na+/Cl- -dependent neurotransmitter transporters: drugs, substrates, presynaptic receptors, and signaling systems.

Authors:  N R Zahniser; S Doolen
Journal:  Pharmacol Ther       Date:  2001-10       Impact factor: 12.310

2.  Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism.

Authors:  C Saunders; J V Ferrer; L Shi; J Chen; G Merrill; M E Lamb; L M Leeb-Lundberg; L Carvelli; J A Javitch; A Galli
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 3.  The family of Na+/Cl- neurotransmitter transporters.

Authors:  N Nelson
Journal:  J Neurochem       Date:  1998-11       Impact factor: 5.372

4.  Characterization of extracellular dopamine clearance in the medial prefrontal cortex: role of monoamine uptake and monoamine oxidase inhibition.

Authors:  H K Wayment; J O Schenk; B A Sorg
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

5.  Toward development of an in vitro model of methamphetamine-induced dopamine nerve terminal toxicity.

Authors:  S Kim; R Westphalen; B Callahan; G Hatzidimitriou; J Yuan; G A Ricaurte
Journal:  J Pharmacol Exp Ther       Date:  2000-05       Impact factor: 4.030

6.  Dopamine transporter antagonists block phorbol ester-induced dopamine release and dopamine transporter phosphorylation in striatal synaptosomes.

Authors:  R M Cowell; L Kantor; G H Hewlett; K A Frey; M E Gnegy
Journal:  Eur J Pharmacol       Date:  2000-02-11       Impact factor: 4.432

7.  Methamphetamine decreases mouse striatal dopamine transporter activity: roles of hyperthermia and dopamine.

Authors:  V Sandoval; G R Hanson; A E Fleckenstein
Journal:  Eur J Pharmacol       Date:  2000-12-15       Impact factor: 4.432

8.  Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model.

Authors:  V Sandoval; E L Riddle; Y V Ugarte; G R Hanson; A E Fleckenstein
Journal:  J Neurosci       Date:  2001-02-15       Impact factor: 6.167

9.  Dopamine D1 receptors synergize with D2, but not D3 or D4, receptors in the striatum without the involvement of action potentials.

Authors:  G J LaHoste; B L Henry; J F Marshall
Journal:  J Neurosci       Date:  2000-09-01       Impact factor: 6.167

10.  Transport rates of GABA transporters: regulation by the N-terminal domain and syntaxin 1A.

Authors:  S L Deken; M L Beckman; L Boos; M W Quick
Journal:  Nat Neurosci       Date:  2000-10       Impact factor: 24.884

View more
  36 in total

1.  Rab11 supports amphetamine-stimulated norepinephrine transporter trafficking.

Authors:  Heinrich J G Matthies; Jessica L Moore; Christine Saunders; Dawn Signor Matthies; Lynne A Lapierre; James R Goldenring; Randy D Blakely; Aurelio Galli
Journal:  J Neurosci       Date:  2010-06-09       Impact factor: 6.167

2.  PKCbeta co-localizes with the dopamine transporter in mesencephalic neurons.

Authors:  Heather A O'Malley; Yanghae Park; Lori L Isom; Margaret E Gnegy
Journal:  Neurosci Lett       Date:  2010-08-09       Impact factor: 3.046

3.  Dopamine transporter endocytic trafficking in striatal dopaminergic neurons: differential dependence on dynamin and the actin cytoskeleton.

Authors:  Luke R Gabriel; Sijia Wu; Patrick Kearney; Karl D Bellvé; Clive Standley; Kevin E Fogarty; Haley E Melikian
Journal:  J Neurosci       Date:  2013-11-06       Impact factor: 6.167

4.  Amphetamine maintenance differentially modulates effects of cocaine, methylenedioxypyrovalerone (MDPV), and methamphetamine on intracranial self-stimulation and nucleus accumbens dopamine in rats.

Authors:  Amy R Johnson; Matthew L Banks; Dana E Selley; S Stevens Negus
Journal:  Neuropsychopharmacology       Date:  2018-04-19       Impact factor: 7.853

Review 5.  Trafficking of dopamine transporters in psychostimulant actions.

Authors:  Nancy R Zahniser; Alexander Sorkin
Journal:  Semin Cell Dev Biol       Date:  2009-01-22       Impact factor: 7.727

6.  Involvement of threonine 258 and serine 259 motif in amphetamine-induced norepinephrine transporter endocytosis.

Authors:  Balasubramaniam Annamalai; Padmanabhan Mannangatti; Obulakshmi Arapulisamy; Sammanda Ramamoorthy; Lankupalle D Jayanthi
Journal:  J Neurochem       Date:  2010-07-30       Impact factor: 5.372

Review 7.  The dopamine transporter: An unrecognized nexus for dysfunctional peripheral immunity and signaling in Parkinson's Disease.

Authors:  Phillip Mackie; Joe Lebowitz; Leila Saadatpour; Emily Nickoloff; Peter Gaskill; Habibeh Khoshbouei
Journal:  Brain Behav Immun       Date:  2018-03-15       Impact factor: 7.217

8.  Daily monitoring of dopamine efflux reveals a short-lasting occlusion of the dopamine agonist properties of d-amphetamine by dopamine transporter blockers GBR 12909 and methylphenidate.

Authors:  Soyon Ahn; Anthony G Phillips
Journal:  ACS Chem Neurosci       Date:  2013-05-03       Impact factor: 4.418

9.  Differential targeting of the dopamine transporter to recycling or degradative pathways during amphetamine- or PKC-regulated endocytosis in dopamine neurons.

Authors:  Weimin C Hong; Susan G Amara
Journal:  FASEB J       Date:  2013-04-23       Impact factor: 5.191

10.  Rapid substrate-induced down-regulation in function and surface localization of dopamine transporters: rat dorsal striatum versus nucleus accumbens.

Authors:  Toni L Richards; Nancy R Zahniser
Journal:  J Neurochem       Date:  2009-01-22       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.